IDEXX Laboratories, Inc.
IDXX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.51 | 2.16 | -7.08 | 2.68 |
| FCF Yield | 2.34% | 1.68% | 1.16% | 1.13% |
| EV / EBITDA | 27.27 | 38.37 | 34.96 | 54.80 |
| Quality | ||||
| ROIC | 33.87% | 32.93% | 32.48% | 41.75% |
| Gross Margin | 61.04% | 59.82% | 59.52% | 58.76% |
| Cash Conversion Ratio | 1.05 | 1.07 | 0.80 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.99% | 4.42% | 7.55% | 10.13% |
| Free Cash Flow Growth | 3.26% | 96.09% | -38.03% | 17.68% |
| Safety | ||||
| Net Debt / EBITDA | 0.55 | 0.50 | 1.34 | 0.85 |
| Interest Coverage | 36.16 | 26.39 | 22.55 | 31.27 |
| Efficiency | ||||
| Inventory Turnover | 3.98 | 3.87 | 3.71 | 4.93 |
| Cash Conversion Cycle | 116.90 | 119.70 | 122.20 | 90.40 |